Alere Hit With Another Federal Subpoena, Casting More Doubt On Abbott Deal

The company says the matters under investigation are immaterial, but the stock market disagrees, taking about a billion dollars from embattled diagnostics company in under a half-hour.

More from Business

More from Medtech Insight